{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:21:18Z","timestamp":1792138878561,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the S&T Program of Hebei","award":["22377711D"],"award-info":[{"award-number":["22377711D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12035-024-04588-5","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:04:54Z","timestamp":1730473494000},"page":"4785-4801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BTK and YKL-40 Levels and Their Association with Acute AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1007","volume":"62","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"3","key":"4588_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ijms17030273","volume":"17","author":"M Jasiak-Zatonska","year":"2016","unstructured":"Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W (2016) The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci 17(3):273. https:\/\/doi.org\/10.3390\/ijms17030273","journal-title":"Int J Mol Sci"},{"key":"4588_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.14670\/hh-20.945","volume":"20","author":"C Brunner","year":"2005","unstructured":"Brunner C, M\u00fcller B, Wirth T (2005) Bruton\u2019s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 20:945\u201355. https:\/\/doi.org\/10.14670\/hh-20.945","journal-title":"Histol Histopathol"},{"key":"4588_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14728214.2020.1822817","volume":"25","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Correale J (2020) Bruton\u2019s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs 25:377\u2013381. https:\/\/doi.org\/10.1080\/14728214.2020.1822817","journal-title":"Expert Opin Emerg Drugs"},{"key":"4588_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","volume":"38","author":"J Rip","year":"2018","unstructured":"Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OBJ (2018) The role of Bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol 38:17\u201362. https:\/\/doi.org\/10.1615\/CritRevImmunol.2018025184","journal-title":"Crit Rev Immunol"},{"key":"4588_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","volume":"152","author":"CI Smith","year":"1994","unstructured":"Smith CI, Baskin B, Humire-Greiff P et al (1994) Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 152:557\u201365","journal-title":"J Immunol"},{"key":"4588_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","volume":"140","author":"S Torke","year":"2020","unstructured":"Torke S, Pretzsch R, H\u00e4usler D et al (2020) Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol 140:535\u2013548. https:\/\/doi.org\/10.1007\/s00401-020-02204-z","journal-title":"Acta Neuropathol"},{"key":"4588_CR7","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/j.1742-4658.2011.08073.x","volume":"278","author":"W Ellmeier","year":"2011","unstructured":"Ellmeier W, Abramova A, Schebesta A (2011) Tec family kinases: regulation of Fc\u03b5RI-mediated mast-cell activation. Febs j 278:1990\u20132000. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08073.x","journal-title":"Febs j"},{"key":"4588_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.187.8.1235","volume":"187","author":"D Hata","year":"1998","unstructured":"Hata D, Kawakami Y, Inagaki N et al (1998) Involvement of Bruton\u2019s tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med 187:1235\u20131247. https:\/\/doi.org\/10.1084\/jem.187.8.1235","journal-title":"J Exp Med"},{"key":"4588_CR9","doi-asserted-by":"publisher","first-page":"40261","DOI":"10.1074\/jbc.M506063200","volume":"280","author":"S Iwaki","year":"2005","unstructured":"Iwaki S, Tkaczyk C, Satterthwaite AB et al (2005) Btk plays a crucial role in the amplification of Fc epsilon RI-mediated mast cell activation by kit. J Biol Chem 280:40261\u201340270. https:\/\/doi.org\/10.1074\/jbc.M506063200","journal-title":"J Biol Chem"},{"key":"4588_CR10","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1002\/jcp.29224","volume":"235","author":"M Li","year":"2020","unstructured":"Li M, Guo Q, Cai H, Wang H, Ma Z, Zhang X (2020) miR-218 regulates diabetic nephropathy via targeting IKK-\u03b2 and modulating NK-\u03baB-mediated inflammation. J Cell Physiol 235:3362\u20133371. https:\/\/doi.org\/10.1002\/jcp.29224","journal-title":"J Cell Physiol"},{"key":"4588_CR11","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Merino A (2021) Bruton\u2019s tyrosine kinase inhibitors: a new generation of promising agents for multiple sclerosis therapy. Cells 10 https:\/\/doi.org\/10.3390\/cells10102560","DOI":"10.3390\/cells10102560"},{"issue":"9","key":"4588_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallstr\u00f6m E, Tolebrutinib Phase 2b Study Group et al (2021) Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 20(9):729\u2013738. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","journal-title":"Lancet Neurol"},{"key":"4588_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40001-022-00723-x","volume":"27","author":"H Qiao","year":"2022","unstructured":"Qiao H, Mao Z, Wang W et al (2022) Changes in the BTK\/NF-\u03baB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders. Eur J Med Res 27:96. https:\/\/doi.org\/10.1186\/s40001-022-00723-x","journal-title":"Eur J Med Res"},{"key":"4588_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12974-023-02997-2","volume":"20","author":"Y Liu","year":"2023","unstructured":"Liu Y, Huang Z, Zhang TX et al (2023) Bruton\u2019s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder. J Neuroinflammation 20:309. https:\/\/doi.org\/10.1186\/s12974-023-02997-2","journal-title":"J Neuroinflammation"},{"key":"4588_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https:\/\/doi.org\/10.1186\/1742-2094-9-14","journal-title":"J Neuroinflammation"},{"issue":"7","key":"4588_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, Sepulveda M, Armangue T, Blanco Y, Rost\u00e1sy K, Calvo AC, Olascoaga J, Rami\u00f3-Torrent\u00e0 L et al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21(7):866\u2013874. https:\/\/doi.org\/10.1177\/1352458514555785","journal-title":"Mult Scler"},{"issue":"3","key":"4588_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ene.12898","volume":"23","author":"ED van Pelt","year":"2016","unstructured":"van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ (2016) Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 23(3):580\u2013587. https:\/\/doi.org\/10.1111\/ene.12898","journal-title":"Eur J Neurol"},{"key":"4588_CR18","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/wnl.0000000000200052","volume":"98","author":"MW H\u00fcmmert","year":"2022","unstructured":"H\u00fcmmert MW, Sch\u00f6ppe LM, Bellmann-Strobl J et al (2022) Costs and health-related quality of life in patients with NMO spectrum disorders and 3 MOG-antibody associated disease (CHANCENMO-Study). Neurology 98:e1184\u2013e1196. https:\/\/doi.org\/10.1212\/wnl.0000000000200052","journal-title":"Neurology"},{"key":"4588_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815. https:\/\/doi.org\/10.1016\/s1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"key":"4588_CR20","doi-asserted-by":"publisher","first-page":"9853192","DOI":"10.1155\/2018\/9853192","volume":"2018","author":"AA Abd El-Fattah","year":"2018","unstructured":"Abd El-Fattah AA, Sadik NAH, Shaker OG, Mohamed Kamal A (2018) Single nucleotide polymorphism in SMAD7 and CHI3L1 and colorectal cancer risk. Mediators Inflamm 2018:9853192. https:\/\/doi.org\/10.1155\/2018\/9853192","journal-title":"Mediators Inflamm"},{"key":"4588_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","volume":"73","author":"CG Lee","year":"2011","unstructured":"Lee CG, Da Silva CA, Dela Cruz CS et al (2011) Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 73:479\u2013501. https:\/\/doi.org\/10.1146\/annurev-physiol-012110-142250","journal-title":"Annu Rev Physiol"},{"key":"4588_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12974-018-1269-3","volume":"15","author":"JY Choi","year":"2018","unstructured":"Choi JY, Yeo IJ, Kim KC et al (2018) K284\u20136111 prevents the amyloid beta-induced neuroinflammation and impairment of recognition memory through inhibition of NF-\u03baB-mediated CHI3L1 expression. J Neuroinflammation 15:224. https:\/\/doi.org\/10.1186\/s12974-018-1269-3","journal-title":"J Neuroinflammation"},{"key":"4588_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1742-2094-7-34","volume":"7","author":"D Bonneh-Barkay","year":"2010","unstructured":"Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA (2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 7:34. https:\/\/doi.org\/10.1186\/1742-2094-7-34","journal-title":"J Neuroinflammation"},{"key":"4588_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00296-010-1727-4","volume":"32","author":"G G\u00fcngen","year":"2012","unstructured":"G\u00fcngen G, Ardic F, F\u0131nd\u0131ko\u011flu G, Rota S (2012) The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis. Rheumatol Int 32:1235\u20131244. https:\/\/doi.org\/10.1007\/s00296-010-1727-4","journal-title":"Rheumatol Int"},{"key":"4588_CR25","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.msard.2020.102395","volume":"45","author":"Y Qi","year":"2020","unstructured":"Qi Y, Chou LS, Zhang LJ et al (2020) Increased cerebrospinal fluid YKL-40 levels are associated with disease severity of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 45:102395. https:\/\/doi.org\/10.1016\/j.msard.2020.102395","journal-title":"Mult Scler Relat Disord"},{"key":"4588_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729","journal-title":"Neurology"},{"key":"4588_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"4588_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","volume":"265","author":"D Conradsson","year":"2018","unstructured":"Conradsson D, Ytterberg C, von Koch L, Johansson S (2018) Changes in disability in people with multiple sclerosis: a 10-year prospective study. J Neurol 265:119\u2013126. https:\/\/doi.org\/10.1007\/s00415-017-8676-8","journal-title":"J Neurol"},{"key":"4588_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12913-017-2807-x","volume":"17","author":"A Sicras-Mainar","year":"2017","unstructured":"Sicras-Mainar A, Ru\u00edz-Beato E, Navarro-Artieda R, Maurino J (2017) Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res 17:854. https:\/\/doi.org\/10.1186\/s12913-017-2807-x","journal-title":"BMC Health Serv Res"},{"key":"4588_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.40059","volume":"69","author":"OBJ Corneth","year":"2017","unstructured":"Corneth OBJ, Verstappen GMP, Paulissen SMJ et al (2017) Enhanced Bruton\u2019s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol 69:1313\u20131324. https:\/\/doi.org\/10.1002\/art.40059","journal-title":"Arthritis Rheumatol"},{"key":"4588_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10067-017-3717-3","volume":"37","author":"W Kong","year":"2018","unstructured":"Kong W, Deng W, Sun Y et al (2018) Increased expression of Bruton\u2019s tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol 37:43\u201349. https:\/\/doi.org\/10.1007\/s10067-017-3717-3","journal-title":"Clin Rheumatol"},{"key":"4588_CR32","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/rheumatology\/kez205","volume":"58","author":"A von Borstel","year":"2019","unstructured":"von Borstel A, Abdulahad WH, Sanders JS et al (2019) Evidence for enhanced Bruton\u2019s tyrosine kinase activity in transitional and na\u00efve B cells of patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 58:2230\u20132239. https:\/\/doi.org\/10.1093\/rheumatology\/kez205","journal-title":"Rheumatology (Oxford)"},{"key":"4588_CR33","doi-asserted-by":"publisher","unstructured":"Rijvers L, van Langelaar J, Bogers L et al (2022) Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. JCI Insight 7 https:\/\/doi.org\/10.1172\/jci.insight.160909","DOI":"10.1172\/jci.insight.160909"},{"key":"4588_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12974-023-02896-6","volume":"20","author":"HJ Kim","year":"2023","unstructured":"Kim HJ, Park JE, Shin W et al (2023) Distinct features of B cell receptors in neuromyelitis optica spectrum disorder among CNS inflammatory demyelinating diseases. J Neuroinflammation 20:225. https:\/\/doi.org\/10.1186\/s12974-023-02896-6","journal-title":"J Neuroinflammation"},{"key":"4588_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr TA, Shen P, Brown S et al (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209:1001\u20131010. https:\/\/doi.org\/10.1084\/jem.20111675","journal-title":"J Exp Med"},{"key":"4588_CR36","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/nxi.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O\u2019Connor KC, Bar-Or A et al (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e104. https:\/\/doi.org\/10.1212\/nxi.0000000000000104","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4588_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H et al (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89:13\u201323. https:\/\/doi.org\/10.1002\/ana.25927","journal-title":"Ann Neurol"},{"key":"4588_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/clinchem\/44.3.509","volume":"44","author":"S Harvey","year":"1998","unstructured":"Harvey S, Weisman M, O\u2019Dell J et al (1998) Chondrex: new marker of joint disease. Clin Chem 44:509\u201316","journal-title":"Clin Chem"},{"key":"4588_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/030097401753180381","volume":"30","author":"JS Johansen","year":"2001","unstructured":"Johansen JS, Kirwan JR, Price PA, Sharif M (2001) Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol 30:297\u2013304. https:\/\/doi.org\/10.1080\/030097401753180381","journal-title":"Scand J Rheumatol"},{"key":"4588_CR40","first-page":"655","volume":"19","author":"T Matsumoto","year":"2001","unstructured":"Matsumoto T, Tsurumoto T (2001) Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 19:655\u201360","journal-title":"Clin Exp Rheumatol"},{"key":"4588_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00296-012-2387-3","volume":"33","author":"M Kazakova","year":"2013","unstructured":"Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V (2013) Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int 33:341\u2013346. https:\/\/doi.org\/10.1007\/s00296-012-2387-3","journal-title":"Rheumatol Int"},{"key":"4588_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s002960100115","volume":"20","author":"R Peltomaa","year":"2001","unstructured":"Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M (2001) Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 20:192\u2013196. https:\/\/doi.org\/10.1007\/s002960100115","journal-title":"Rheumatol Int"},{"key":"4588_CR43","doi-asserted-by":"publisher","first-page":"2212480","DOI":"10.1080\/19932820.2023.2212480","volume":"18","author":"YD Chen","year":"2023","unstructured":"Chen YD, Huang CY, Wang ZP, Wang W (2023) Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves\u2019 disease. Libyan J Med 18:2212480. https:\/\/doi.org\/10.1080\/19932820.2023.2212480","journal-title":"Libyan J Med"},{"key":"4588_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1590\/0004-282x-anp-2020-0326","volume":"79","author":"A D\u00f6nder","year":"2021","unstructured":"D\u00f6nder A, \u00d6zdemir HH (2021) Serum YKL-40 levels in patients with multiple sclerosis. Arq Neuropsiquiatr 79:795\u2013798. https:\/\/doi.org\/10.1590\/0004-282x-anp-2020-0326","journal-title":"Arq Neuropsiquiatr"},{"key":"4588_CR45","first-page":"172","volume":"53","author":"JS Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172\u2013209","journal-title":"Dan Med Bull"},{"key":"4588_CR46","first-page":"229","volume":"105","author":"S Uysal","year":"2014","unstructured":"Uysal S, Meri\u00e7 Yilmaz F, Bo\u011fdaycio\u011flu N, Mungan \u00d6zt\u00fcrk S, Ak F (2014) Increased serum levels of some inflammatory markers in patients with multiple sclerosis. Minerva Med 105:229\u201335","journal-title":"Minerva Med"},{"key":"4588_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1006\/excr.1999.4511","volume":"250","author":"KM Malinda","year":"1999","unstructured":"Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168\u2013173. https:\/\/doi.org\/10.1006\/excr.1999.4511","journal-title":"Exp Cell Res"},{"key":"4588_CR48","first-page":"351","volume":"110","author":"B Volck","year":"1998","unstructured":"Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351\u201360","journal-title":"Proc Assoc Am Physicians"},{"key":"4588_CR49","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/1529-0131(200006)43:6<1233::Aid-anr6>3.0.Co;2-9","volume":"43","author":"D Baeten","year":"2000","unstructured":"Baeten D, Boots AM, Steenbakkers PG et al (2000) Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43:1233\u20131243. https:\/\/doi.org\/10.1002\/1529-0131(200006)43:6%3c1233::Aid-anr6%3e3.0.Co;2-9","journal-title":"Arthritis Rheum"},{"key":"4588_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s13365-015-0323-5","volume":"21","author":"I Guendel","year":"2015","unstructured":"Guendel I, Iordanskiy S, Sampey GC et al (2015) Role of Bruton\u2019s tyrosine kinase inhibitors in HIV-1-infected cells. J Neurovirol 21:257\u2013275. https:\/\/doi.org\/10.1007\/s13365-015-0323-5","journal-title":"J Neurovirol"},{"key":"4588_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17:57. https:\/\/doi.org\/10.1186\/s12943-018-0779-z","journal-title":"Mol Cancer"},{"key":"4588_CR52","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","volume":"8","author":"ANR Weber","year":"2017","unstructured":"Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C (2017) Bruton\u2019s tyrosine kinase: an emerging key player in innate immunity. Front Immunol 8:1454. https:\/\/doi.org\/10.3389\/fimmu.2017.01454","journal-title":"Front Immunol"},{"key":"4588_CR53","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, Liu X, Cao X, Xu S (2020) T-cell expression of Bruton\u2019s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol 17:1042\u20131052. https:\/\/doi.org\/10.1038\/s41423-019-0270-9","journal-title":"Cell Mol Immunol"},{"key":"4588_CR54","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","volume":"132","author":"A Bercusson","year":"2018","unstructured":"Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D (2018) Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood 132:1985\u20131988. https:\/\/doi.org\/10.1182\/blood-2017-12-823393","journal-title":"Blood"},{"key":"4588_CR55","doi-asserted-by":"publisher","first-page":"e85834","DOI":"10.1371\/journal.pone.0085834","volume":"9","author":"J Ng","year":"2014","unstructured":"Ng J, Hams E, Smith S et al (2014) Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS ONE 9:e85834. https:\/\/doi.org\/10.1371\/journal.pone.0085834","journal-title":"PLoS ONE"},{"key":"4588_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00109-019-01777-x","volume":"97","author":"M Pontoriero","year":"2019","unstructured":"Pontoriero M, Fiume G, Vecchio E et al (2019) Activation of NF-\u03baB in B cell receptor signaling through Bruton\u2019s tyrosine kinase-dependent phosphorylation of I\u03baB-\u03b1. J Mol Med (Berl) 97:675\u2013690. https:\/\/doi.org\/10.1007\/s00109-019-01777-x","journal-title":"J Mol Med (Berl)"},{"key":"4588_CR57","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","volume":"11","author":"AM Agasing","year":"2020","unstructured":"Agasing AM, Wu Q, Khatri B et al (2020) Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun 11:2856. https:\/\/doi.org\/10.1038\/s41467-020-16625-7","journal-title":"Nat Commun"},{"key":"4588_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-016-0355-y","volume":"4","author":"B Zeka","year":"2016","unstructured":"Zeka B, Hastermann M, Kaufmann N et al (2016) Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO\/SD. Acta Neuropathol Commun 4:82. https:\/\/doi.org\/10.1186\/s40478-016-0355-y","journal-title":"Acta Neuropathol Commun"},{"key":"4588_CR59","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awy010","volume":"141","author":"R Wilson","year":"2018","unstructured":"Wilson R, Makuch M, Kienzler AK et al (2018) Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain 141:1063\u20131074. https:\/\/doi.org\/10.1093\/brain\/awy010","journal-title":"Brain"},{"key":"4588_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.23651","volume":"72","author":"M Varrin-Doyer","year":"2012","unstructured":"Varrin-Doyer M, Spencer CM, Schulze-Topphoff U et al (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53\u201364. https:\/\/doi.org\/10.1002\/ana.23651","journal-title":"Ann Neurol"},{"key":"4588_CR61","doi-asserted-by":"publisher","first-page":"662223","DOI":"10.3389\/fimmu.2021.662223","volume":"12","author":"GE Ringheim","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K (2021) Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol 12:662223. https:\/\/doi.org\/10.3389\/fimmu.2021.662223","journal-title":"Front Immunol"},{"key":"4588_CR62","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s1474-4422(21)00250-7","volume":"20","author":"J Correale","year":"2021","unstructured":"Correale J (2021) BTK inhibitors as potential therapies for multiple sclerosis. Lancet Neurol 20:689\u2013691. https:\/\/doi.org\/10.1016\/s1474-4422(21)00250-7","journal-title":"Lancet Neurol"},{"key":"4588_CR63","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS et al (2019) Evobrutinib Phase 2 Study Group Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 380:2406\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa1901981","journal-title":"N Engl J Med"},{"key":"4588_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P et al (2021) Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 20:729\u2013738. https:\/\/doi.org\/10.1016\/s1474-4422(21)00237-4","journal-title":"Lancet Neurol"},{"key":"4588_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/b978-0-12-800100-4.00006-4","volume":"121","author":"M Levy","year":"2014","unstructured":"Levy M, Wildemann B, Jarius S et al (2014) Immunopathogenesis of neuromyelitis optica. Adv Immunol 121:213\u2013242. https:\/\/doi.org\/10.1016\/b978-0-12-800100-4.00006-4","journal-title":"Adv Immunol"},{"key":"4588_CR66","doi-asserted-by":"publisher","unstructured":"Fujihara K, Bennett JL, de Seze J et al (2020) Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7 https:\/\/doi.org\/10.1212\/nxi.0000000000000841","DOI":"10.1212\/nxi.0000000000000841"},{"key":"4588_CR67","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","volume":"16","author":"A Uzawa","year":"2010","unstructured":"Uzawa A, Mori M, Arai K et al (2010) Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16:1443\u20131452. https:\/\/doi.org\/10.1177\/1352458510379247","journal-title":"Mult Scler"},{"key":"4588_CR68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bpa.12097","volume":"24","author":"A Uzawa","year":"2014","unstructured":"Uzawa A, Mori M, Kuwabara S (2014) Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol 24:67\u201373. https:\/\/doi.org\/10.1111\/bpa.12097","journal-title":"Brain Pathol"},{"key":"4588_CR69","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12883-021-02432-0","volume":"21","author":"H Xie","year":"2021","unstructured":"Xie H, Zhao Y, Pan C et al (2021) Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study. BMC Neurol 21:389. https:\/\/doi.org\/10.1186\/s12883-021-02432-0","journal-title":"BMC Neurol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04588-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:07:46Z","timestamp":1741082866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04588-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4588"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04588-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Experimental protocol was approved by the Institutional Animal Care and Use Committee of Hebei Medical University and the Experimental Ethics Committee of the Second Hospital of Hebei Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}